U.S. Markets closed

Vectura Group plc (VEC.L)

LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
110.20-2.70 (-2.39%)
At close: 4:35PM BST
People also watch
VER.LOXB.LBTG.LHIK.LDPH.L

Vectura Group plc

One Prospect West
Chippenham SN14 6FH
United Kingdom
44 1249 667700
http://www.vectura.co.uk

SectorHealthcare
IndustryDrug Manufacturers - Major
Full Time Employees453

Key Executives

NameTitlePayExercisedAge
Mr. Andrew DerodraChief Financial Officer and Exec. Director417kN/A51
Elizabeth KnowlesDirector of Investor Relations & AnalysisN/AN/AN/A
Mr. James Ward-Lilley BA, MBAChief Exec. Officer and Exec. Director1.18MN/A52
Mr. John MurphyGen. Counsel and Company Sec.N/AN/A64
Fleur WoodDirector of CommunicationsN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

Vectura Group plc researches, develops, and commercializes novel therapeutic products and drug delivery systems for the treatment of airways-related diseases. The company’s marketed products include Ultibro Breezhaler and Seebri Breezhaler for the treatment of chronic obstructive pulmonary disease (COPD); AirFlusal Forspiro for the treatment of asthma and COPD; ADVATE for the treatment of haemophilia A; and Adept for the treatment of surgical adhesions. Its generic products include VR315, VR506, and VR632 for the treatment of asthma; and Phase III clinical stage products include VR475 for the treatment of severe adult asthma, and VR876 for the treatment of lung diseases, as well as NVA237 and QVA149 for the treatment of COPD for which filed NDA to the Food and Drug Administration. Its Phase II clinical stage products comprise VR096 for anti-inflammatory asthma and COPD; VR647 for the treatment of paediatric asthma; VR179 for the treatment of cystic fibrosis; and VR736 for the treatment severe influenza. The company’s Phase I clinical stage products include VR942 for the treatment of asthma; VR475 for the treatment of severe adult asthma; and VR465 for the treatment for respiratory syncytial virus infection. Its pre-clinical stage product includes VR588 for the treatment of inflammatory airway diseases. The company also provides patent-protected technology platforms, such as PowderHale, a formulation technology that is designed to enhance the performance of inhaled formulations; PowderMax, a technology that applies PowderHale approach to create high performance dry powder formulations; and ParticleMax, spray drying particle engineering technology to deliver dry powder biologics. In addition, it provides dry powder inhalers; nebulizer delivery systems; and AKITA Jet, APIXNEB, and FOX devices. Vectura Group plc was founded in 1997 and is headquartered in Chippenham, the United Kingdom.

Corporate Governance

Vectura Group plc’s ISS Governance QualityScore as of August 1, 2017 is 3. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 1; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.